These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 19807550)

  • 1. Management and costs of severe psoriasis: the role of new biologics.
    Feldman SR; Pearce DJ
    Expert Rev Pharmacoecon Outcomes Res; 2004 Oct; 4(5):573-9. PubMed ID: 19807550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paradoxical effects of cost reduction measures in managed care systems for treatment of severe psoriasis.
    Yentzer BA; Yelverton CB; Simpson GL; Simpson JF; Hwang W; Balkrishnan R; Feldman SR
    Dermatol Online J; 2009 Apr; 15(4):1. PubMed ID: 19450394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic treatment for moderate to severe psoriasis: estimates of failure rates and direct medical costs in a north-eastern US managed care plan.
    Feldman SR; Evans C; Russell MW
    J Dermatolog Treat; 2005 Feb; 16(1):37-42. PubMed ID: 15897166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes associated with the use of biologic agents in moderate to severe psoriasis.
    Price J; Bhosle M; Feldman SR; Balkrishnan R
    J Drugs Dermatol; 2007 Mar; 6(3):259-67. PubMed ID: 17373187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From conventional to cutting edge: the new era of biologics in treatment of psoriasis.
    Tzu J; Kerdel F
    Dermatol Ther; 2008; 21(2):131-41. PubMed ID: 18394087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease and treatment burden of psoriasis: examining the impact of biologics.
    Raval K; Lofland JH; Waters H; Piech CT
    J Drugs Dermatol; 2011 Feb; 10(2):189-96. PubMed ID: 21283925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Would elimination of copayments for phototherapy decrease the cost of treating psoriasis with systemic biologics? A cost analysis.
    Simpson JF; Yelverton CB; Balkrishnan R; Fleischer A; Lide W; Feldman SR
    Manag Care Interface; 2006 Jun; 19(6):39-43. PubMed ID: 16892660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regarding: Rosenthal DI, Glatstein E. "We've Got a Treatment, but What's the Disease?" The Oncologist 1996;1.
    Lunsford LD; Flickinger JC; Larson D
    Oncologist; 1997; 2(1):59-61. PubMed ID: 10388030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Care of patients with psoriasis: an audit of U.K. services in secondary care.
    Eedy DJ; Griffiths CE; Chalmers RJ; Ormerod AD; Smith CH; Barker JN; Potter J; Ingham J; Lowe D; Burge S
    Br J Dermatol; 2009 Mar; 160(3):557-64. PubMed ID: 19120330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low prescription rate for systemic treatments in the management of severe psoriasis vulgaris and psoriatic arthritis in dermatological practices in Berlin and Brandenburg, Germany: results from a patient registry.
    Nast A; Reytan N; Rosumeck S; Erdmann R; Rzany B
    J Eur Acad Dermatol Venereol; 2008 Nov; 22(11):1337-42. PubMed ID: 18624864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do utilization management controls for phototherapy increase the prescription of biologics?
    Simpson GL; Yelverton CB; Rittenberg S; Feldman SR
    J Dermatolog Treat; 2006; 17(6):359-61. PubMed ID: 17853310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Home ultraviolet B phototherapy: a cost-effective option for severe psoriasis.
    Yelverton CB; Kulkarni AS; Balkrishnan R; Feldman SR
    Manag Care Interface; 2006 Jan; 19(1):33-6, 39. PubMed ID: 16453993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?
    Alwawi EA; Krulig E; Gordon KB
    Dermatol Ther; 2009; 22(5):431-40. PubMed ID: 19845720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psoriasis treatment patterns: results of a cross-sectional survey of dermatologists.
    Patel V; Horn EJ; Lobosco SJ; Fox KM; Stevens SR; Lebwohl M
    J Am Acad Dermatol; 2008 Jun; 58(6):964-9. PubMed ID: 18378352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phototherapy, psoriasis, and the age of biologics.
    Richard EG; Hönigsmann H
    Photodermatol Photoimmunol Photomed; 2014 Feb; 30(1):3-7. PubMed ID: 24313462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decision points for the initiation of systemic treatment for psoriasis.
    Feldman SR; Koo JY; Menter A; Bagel J
    J Am Acad Dermatol; 2005 Jul; 53(1):101-7. PubMed ID: 15965429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the US.
    Crown WH; Bresnahan BW; Orsini LS; Kennedy S; Leonardi C
    Curr Med Res Opin; 2004 Dec; 20(12):1929-36. PubMed ID: 15701211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of the two-compound formulation calcipotriol and betamethasone dipropionate compared with commonly used topical treatments in the management of moderately severe plaque psoriasis in Scotland.
    Bottomley JM; Auland ME; Morais J; Boyd G; Douglas WS
    Curr Med Res Opin; 2007 Aug; 23(8):1887-901. PubMed ID: 17610804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness and impact on quality of life of alefacept in the treatment of psoriasis.
    Scheinfeld N; Parish D
    Expert Rev Pharmacoecon Outcomes Res; 2007 Dec; 7(6):545-57. PubMed ID: 20528318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
    Mazzotta A; Esposito M; Costanzo A; Chimenti S
    Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.